KRAS and serous adenocarcinoma: Nevertheless, a significant difference is observed for the KRAS exon 12 mutation status (p = 0.007), with 77.1% (37 cases) of high-grade serous carcinoma patients having a mutant allele, compared to 95.9% (47 cases) among those with other malignant epithelial tumors.